159 related articles for article (PubMed ID: 820422)
21. Hexamethylmelamine in advanced head and neck cancer. A phase II study.
Gad-El-Mawla N; Macdonald JS; Khaled H
Am J Clin Oncol; 1984 Jun; 7(3):205-8. PubMed ID: 6428214
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
Pisoni MB; Libretti A; Piazza E; Vago G; Scapaticci R; Bianchi C; Tomirotti M; Scanni A; Calzavara MP; Cassani L; Scarpazza G; Marsoni S; Morasca L
Cancer Treat Rep; 1981; 65(7-8):731-2. PubMed ID: 6788372
[No Abstract] [Full Text] [Related]
23. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.
Omura GA; Broun GO; Papps J; Birch R
Cancer Treat Rep; 1981; 65(11-12):1027-9. PubMed ID: 6794907
[TBL] [Abstract][Full Text] [Related]
25. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
26. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
27. Hexamethylmelamine as a single agent in the treatment of small-cell carcinoma of the lung.
Goldsweig HG; Edgerton F; Redden CS; Takita H; Garza JG; Bisel HF
Am J Clin Oncol; 1982 Jun; 5(3):267-72. PubMed ID: 6282109
[No Abstract] [Full Text] [Related]
28. Combined effects of host antitumor immune responses and chemotherapy. Studies with hexamethylmelamine.
Tricarico M; Fuschiotti P; Ricci F; De Filippi R; Nunziata C; Pastore S; De Vecchis L
Chemioterapia; 1988 Jun; 7(3):203-7. PubMed ID: 3139307
[TBL] [Abstract][Full Text] [Related]
29. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
30. Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.
Lake LM; Grunden EE; Johnson BM
Cancer Res; 1975 Oct; 35(10):2858-63. PubMed ID: 808270
[TBL] [Abstract][Full Text] [Related]
31. Controlled studies with bleomycin in solid tumors and lymphomas.
Bonadonna G; Tancini G; Bajetta E
Prog Biochem Pharmacol; 1976; 11():172-84. PubMed ID: 63961
[No Abstract] [Full Text] [Related]
32. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
[No Abstract] [Full Text] [Related]
33. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Gershanovich ML; Livshits ME; Antipenkova VI
Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
[TBL] [Abstract][Full Text] [Related]
34. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR; Faulds D
Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
[TBL] [Abstract][Full Text] [Related]
35. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Krauss S; Tornyos K; DeSimone P; Lowenbraun S; McKeown J; Solomon A; Sonoda T
Cancer Treat Rep; 1979 Mar; 63(3):391-3. PubMed ID: 106964
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
37. Hexamethylmelamine: a critical review of an active drug.
Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
Lawson D; Moore M; Smalley R
Cancer Clin Trials; 1980; 3(4):293-6. PubMed ID: 6775826
[TBL] [Abstract][Full Text] [Related]
40. Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
Wilson WL; Andrews NC; Frelick RW; Nealon TF; Bick RL; Adams T
Cancer Treat Rep; 1976 Mar; 60(3):269-71. PubMed ID: 816467
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]